AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2022
Dec 29, 2022
31542_dirs_2022-12-29_1b2c6051-0551-4736-9eb5-8eee271ab781.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2022-12-27
Reporting Person: Sundaram Preethi (Chief Strategy Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-27 | Options to purchase common stock | $18.59 | A | 68000 | Acquired | 2029-12-27 | Common Stock (68000) | Direct |
| 2022-12-27 | Restricted stock units | $ | A | 20000 | Acquired | Common Stock (20000) | Direct |
Footnotes
F1: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025.
F2: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F3: Shares of common stock will be delivered to the Reporting Person upon vesting.
More from CATALYST PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 11
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Regulatory Filings
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6
Director's Dealing
2025
Dec 30